Zanubrutinib: all 149 studies that test it

Page 2 of 2. Open to participants first (80), then studies with results posted, then the rest; newest registration first within each.

• A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström MacroglobulinemiaActive, not recruitingNCT07169331Phase 4
• A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy AdultsCompletedNCT07141511Phase 1
• Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive, not recruitingNCT06824701Phase 1
• Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Active, not recruitingNCT06647732Phase 2
• Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Active, not recruitingNCT06547944Phase 1
• Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaActive, not recruitingNCT06504199Phase 2
• Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT06073821Phase 3
• Zanubrutinib in Primary Cold Agglutinin DiseaseActive, not recruitingNCT06067048Phase 2
• A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaActive, not recruitingNCT05952037Phase 2
• Prospective Clinical Study of ZPR Regimen in Elderly Treatment-naive Diffuse Large B-cell LymphomaCompletedNCT05940064Phase 2
• Zanubrutinib Treatment in Patients With IgM Monoclonal Gammopathy and Antri-MAG Related PolyneuropathyActive, not recruitingNCT05939037Phase 2
• GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT05797948Not applicable
• Bioequivalence of a Zanubrutinib Tablet Compared to Capsules in Healthy Adult ParticipantsCompletedNCT05767398Phase 1
• Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL PatientsActive, not recruitingNCT05735834Phase 3
• Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL StudyActive, not recruitingNCT05718869Phase 2
• A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous NephropathyActive, not recruitingNCT05707377Phase 2/3
• A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic MalignanciesCompletedNCT05665530Phase 1
• Relative Bioavailability of Zanubrutinib Tablets Compared to Capsules and Effects of Food on the Pharmacokinetics of the Tablet in Healthy AdultsCompletedNCT05547399Phase 1
• R-MTX-zanbrutinib in Secondary CNS LymphomaStatus unknownNCT05398224Phase 2
• Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical TrialStatus unknownNCT05392257Phase 2
• An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult PatientsTerminatedNCT05356858Phase 2
• Zanubrutinib for HLHCompletedNCT05320575Phase 3
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• A Study of Zanubrutinib in Patients With ITPCompletedNCT05279872Phase 2
• Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
• A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
• A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double ExpressionActive, not recruitingNCT05189197Phase 2
• A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone LymphomaActive, not recruitingNCT05100862Phase 3
• Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell LymphomaStatus unknownNCT04899570Phase 2
• Intravitreal MTX and ZR Regimen in Newly Diagnosed PVRLStatus unknownNCT04899453Phase 2
• Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell LymphomaActive, not recruitingNCT04850495Phase 1
• Zanuburutinib in Relapsed and Refractory iMCD: a Prospective, Single-center, Single-arm TrialStatus unknownNCT04743687Phase 2
• Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCLStatus unknownNCT04705129Phase 2
• Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell LymphomaSuspendedNCT04668365Phase 2
• Zanubrutinib in Participants With Active Proliferative Lupus NephritisCompletedNCT04643470Phase 2
• Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLLActive, not recruitingNCT04515238Phase 2
• Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaCompletedNCT04463953Phase 2
• Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruitingNCT04460248Phase 2
• Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT04458610Phase 2
• Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy MalesCompletedNCT04163783Phase 1
• Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy SubjectsCompletedNCT04163523Phase 1
• Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) TreatmentCompletedNCT04116437Phase 2
• A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell TransplantationActive, not recruitingNCT04002297Phase 3
• Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)Active, not recruitingNCT03824483Phase 2
• Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver FunctionCompletedNCT03465059Phase 1
• A Two-Part Phase 1 Study to Investigate the Safety and Tolerability of Supratherapeutic Dose of Zanubrutinib and Effect of Zanubrutinib on Cardiac Repolarization in Healthy SubjectsCompletedNCT03432884Phase 1
• Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy SubjectsCompletedNCT03301181Phase 1
• A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's LymphomaTerminatedNCT02914938Phase 1

← Zanubrutinib overview